|
Eric K. Rowinsky, M.D., became the Chief Medical Officer and Senior Vice President of Clinical Research at Imclone Systems Inc. in 2005. He is also a Clinical Professor of Medicine (Division of Medical Oncology) at the University of Texas Health Science Center, San Antonio. Before assuming his recent position, Dr. Rowinsky, a leader in the field of anticancer drug development, held the position of Director of the Institute of Drug Development at the Cancer Therapy and Research Center’s Institute for Drug Development (IDD) from 2002 to 2004 and was the Director of Clinical Research at the IDD from 1996 to 2002. In addition, he held the SBC Endowed Chair for Early Drug Development at the IDD. He has also served as an Associate Professor of Oncology at Johns Hopkins University until 1996.
Dr. Rowinsky’s research and clinical interests include preclinical, translational, and early clinical and pharmacological studies of novel anticancer drugs, as well as discerning and evaluating developmental and regulatory strategies. He was a longstanding NCI principal investigator on U01 anticancer drug development grants. He is the Editor-in-Chief of Investigational New Drugs, and an Associate Editor of Cancer Research, Clinical Cancer Research, Annals of Oncology, and several other oncology journals. He has served on numerous scientific and oncology advisory boards for biotechnology and pharmaceutical companies, and has advised and/or presented aspects of New Drug Applications to the FDA on several occasions. He serves on the Board of Scientific Counselors of the National Cancer Institute. Among Dr. Rowinsky’s honors include receipt of the career development award of the American Cancer Society and the 6th Annual Emil J. Freireich Award for outstanding achievement of a young researcher in clinical cancer therapeutics and recently represented the AACR as co-chairman of the scientific committee of the 16th EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics, in Geneva, Switzerland. He has published over 230 papers and remains actively involved in preclinical and clinical research.
Professor Rowinsky received a BA degree from New York University and an MD degree from the Vanderbilt University School of Medicine. Following his residency in internal medicine, he completed fellowship training in medical oncology at the Johns Hopkins University School of Medicine and served on the faculty of the Department of Oncology in 1996. | 